Cypress Capital Group Sells 2,882 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Cypress Capital Group lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 47,951 shares of the biopharmaceutical company’s stock after selling 2,882 shares during the period. Cypress Capital Group’s holdings in Gilead Sciences were worth $2,999,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in GILD. Athena Capital Advisors LLC purchased a new position in Gilead Sciences in the 4th quarter worth about $27,000. Capital Financial Planning LLC bought a new position in Gilead Sciences in the 4th quarter worth approximately $27,000. Advisors Preferred LLC bought a new position in Gilead Sciences in the 4th quarter worth approximately $31,000. Legacy Financial Advisors Inc. boosted its stake in Gilead Sciences by 361.3% in the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 383 shares during the period. Finally, Claybrook Capital LLC bought a new position in Gilead Sciences in the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

In other news, Director John Francis Cogan sold 2,700 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total value of $173,178.00. Following the completion of the transaction, the director now directly owns 57,560 shares in the company, valued at $3,691,898.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gayle E. Wilson sold 19,068 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the transaction, the director now owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The disclosure for this sale can be found here. In the last three months, insiders sold 44,802 shares of company stock valued at $2,956,422. Corporate insiders own 0.20% of the company’s stock.

Several research analysts have weighed in on the company. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $69.00 price target for the company in a research note on Tuesday. Cantor Fitzgerald restated a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a report on Thursday. Oppenheimer set a $85.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, March 19th. BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Maxim Group restated a “buy” rating and set a $84.00 price target on shares of Gilead Sciences in a report on Friday, March 29th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $80.94.

GILD stock traded up $1.01 during trading on Friday, reaching $65.15. 7,925,868 shares of the company traded hands, compared to its average volume of 7,466,775. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61. The company has a market cap of $80.37 billion, a P/E ratio of 10.59, a PEG ratio of 4.15 and a beta of 1.16. The company has a debt-to-equity ratio of 1.19, a current ratio of 3.38 and a quick ratio of 3.30.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing analysts’ consensus estimates of $1.70 by ($0.26). The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. Gilead Sciences’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.78 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 6.3 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.87%. The ex-dividend date was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.98%.

COPYRIGHT VIOLATION WARNING: “Cypress Capital Group Sells 2,882 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)” was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/cypress-capital-group-decreases-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Further Reading: What is the price-to-earnings growth (PEG) ratio?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.